Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab immunologic effects after kidney transplantation
NL-OMON50147Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Single-arm trial of iscalimab in kidney transplant, sponsored by Erasmus MC. Primary endpoints: Immune cell number and phenotype, T-cell and B-cell interaction and 3 more. Started Oct 2019; status: active, not recruiting.
02
Drugs
iscalimab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON50147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50147.